

To:

Head of Paediatric Medicines
European Medicines Agency

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Actives substances(s): expanded human autologous mesenchymal adult stem cells extracted from adipose tissue (CX-401)

Invented name: N/A

Latest Decision number(s): 1) P/20/2010

Corresponding PIP number(s): 1) EMEA-000635-PIP01-09

Date of initial marketing authorisation granted: N/A

Date of authorisation of new indication, pharmaceutical form or route of administration: N/A

Please note that development of the medicinal product above in the following
condition(s)/indication(s):

Anal fistula of cryptoglandular aetiology (Non-Crohn)

Anal fistula of Crohn 's disease associated aetiology

Non-inflammatory anal fistula

☒ has been discontinued

☐ has been suspended/put on long-term hold (with possible re-start at a later time)

for the following reason(s): (tick all that apply)

☐ (possible) lack of efficacy in adults

☐ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☐ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)

☒ other reason (please specify: change in the strategy for development)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

In 2018 Takeda Pharmaceutical acquired TiGenix (former Cellerix, S.A.) which became a wholly owned subsidiary of Takeda. Following this acquisition the R&D pipeline of TiGenix was reviewed and it was decided to discontinue the development of Cx401 - the autologous predecessor of Alofisel - since it was outside of Takeda business objectives.

Please note that if the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies to the PIP in question:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Name and signature of the PIP contact point: Signature on file

Date:

20 February 2022

Contact for inquiries from interested parties: Takeda Pharmaceuticals International AG

Telephone: +41-44-555-10-00

Email: giovanni.milazzo@takeda.com